A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine. The two drugs together resulted in greater anti-cancer activity in ATC than either drug alone, says lead researcher Keith Bible, M.D., Ph.D., a Mayo Clinic oncologist. Read more here.
Study mentioned: Isham CR, et al. Pazopanib enhances Paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med. 2013 Jan 2;5(166):166ra3. PMID: 23283368
No comments:
Post a Comment